2024
Investigating synergy between beta-blockers and transarterial chemoembolization in the treatment of hepatocellular carcinoma: preliminary data from a propensity matched analysis
Mutonga M, Shewarega A, Gross M, Kahl V, Madoff D. Investigating synergy between beta-blockers and transarterial chemoembolization in the treatment of hepatocellular carcinoma: preliminary data from a propensity matched analysis. Clinical Imaging 2024, 115: 110283. PMID: 39278042, DOI: 10.1016/j.clinimag.2024.110283.Peer-Reviewed Original ResearchBeta-blockersTumor responseImaging timepointsTumor sizeEtiology of liver diseaseAssociated with high mortalityTransplant free survivalTransplant-free survivalTreatment of hepatocellular carcinomaFavorable clinical outcomesChild-Pugh scoreFirst-line treatmentBeta-blocker groupPredictors of survivalCox regression analysisTreatment of HCCStudent's t-testFree survivalTransarterial chemoembolizationChi-square testPost-TACETACE treatmentPugh scoreSurvival predictorsAdjunctive use
2023
Predictors for Early Liver Cancer Survival After Ablation and Surgical Resection: A Surveillance, Epidemiology, and End Results Program-Medicare Study
Charalel R, Mushlin A, Zheng X, Mao J, Carlos R, Brown R, Fortune B, Talenfeld A, Madoff D, Ibrahim S, Johnson M, Sedrakyan A. Predictors for Early Liver Cancer Survival After Ablation and Surgical Resection: A Surveillance, Epidemiology, and End Results Program-Medicare Study. Journal Of The American College Of Radiology 2023, 21: 295-308. PMID: 37922972, DOI: 10.1016/j.jacr.2023.10.017.Peer-Reviewed Original ResearchCancer-specific mortalityCancer-specific deathSurgical resectionSocial determinantsPortal hypertensionTumor sizeTreatment characteristicsSmall HCCAsian raceDisease factorsMultivariable Cox regression modelsSEER-Medicare studyChronic kidney diseaseHigh-volume centersLarger tumor sizeCox regression modelSignificant protective factorCause mortalityClinical factorsEsophageal varicesIndependent predictorsSEER-MedicareKidney diseaseVolume centersProcedure year
2020
Is There a Role for Combination, Single-Session Selective Transarterial Embolization and Microwave Ablation for Large Renal Masses?
LaRussa S, Vanden Berg RW, Craig KM, Madoff DC, McClure TD. Is There a Role for Combination, Single-Session Selective Transarterial Embolization and Microwave Ablation for Large Renal Masses? CardioVascular And Interventional Radiology 2020, 43: 1468-1473. PMID: 32613266, DOI: 10.1007/s00270-020-02568-5.Peer-Reviewed Original ResearchConceptsLarge renal massTransarterial embolizationRenal tumorsRenal massesMicrowave ablationCharleston Comorbidity IndexLarge renal tumorsEvidence of recurrencePost-procedure complicationsAverage tumor sizeSelective transarterial embolizationSmall renal tumorsClear cell carcinomaMeeting inclusion criteriaPatient demographic informationGroin hematomaComorbidity indexResultsEleven patientsAverage BMICase seriesSuccessful ablationTumor sizeCell carcinomaMean ageRENAL score
2014
Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation
Kluger MD, Halazun KJ, Barroso RT, Fox AN, Olsen SK, Madoff DC, Siegel AB, Weintraub JL, Sussman J, Brown RS, Cherqui D, Emond JC. Bland embolization versus chemoembolization of hepatocellular carcinoma before transplantation. Liver Transplantation 2014, 20: 536-543. PMID: 24493271, PMCID: PMC4095977, DOI: 10.1002/lt.23846.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoma, HepatocellularCase-Control StudiesChemoembolization, TherapeuticDisease-Free SurvivalEnd Stage Liver DiseaseFemaleHumansKaplan-Meier EstimateLiver NeoplasmsLiver TransplantationMaleMiddle AgedNeoplasm Recurrence, LocalRetrospective StudiesTime FactorsTreatment OutcomeConceptsWait-list dropoutTAE patientsTACE patientsTransarterial embolizationTransarterial chemoembolizationHCC patientsEnd-stage liver disease (MELD) scoreSurvival rateRecurrence-free survival ratesMethods of embolizationRadiographic tumor sizeLiver Disease scoreOverall survival rateRecurrence-free survivalKaplan-Meier survivalBland transarterial embolizationCase-control studySignificant demographic differencesExplant tumorsPrimary endpointTreat basisTumor sizeHepatocellular carcinomaDisease scorePatients